Press release Communiqué de presse
Press release Communiqué de presse
November 9, 2018 9 November, 2018
Sernova Retains FronTier Flex for Canadian Investor Relations and Marketing
Source: Sernova Corp.
November 9, 2018 6:00 a.m. EST
LONDON, ONTARIO – November 9, 2018– Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical- stage regenerative medicine company, announces that it has engaged FronTier Flex, an investor relations (IR) and marketing group based in Toronto, Ontario Canada to provide Canadian IR and strategic marketing services.
Sernova President and CEO Dr. Philip Toleikis commented, "FronTier’s engagement falls within the expanded communications strategy Sernova is implementing to help investors and shareholders stay well-informed as we advance our new US diabetes Phase I/II clinical study and other programs. FronTier’s media experience will increase Sernova’s visibility and reach into the investment community through strategic messaging and investor outreach.”
Through their established network of financial industry professionals and marketing service providers, FronTier will assist the corporation by increasing market awareness for the corporation using a number of financial market communications initiatives, including facilitating in-person introductions for the corporation with institutional and retail brokers in Toronto and other financial capitals, and through media distribution on national television, radio and multiple online channels.
Under the terms of the engagement, FronTier has been retained for a 12-month period for aggregate remuneration of $87,000 plus expenses.
About Sernova Corp.
Sernova Corp is developing regenerative medicine therapeutic technologies using an implantable medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin- dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com
For further information contact:
Dominic Gray, Corporate Communications Tel: (519) 858-5126 Dominic.Gray@sernova.com www.sernova.com
Philip Toleikis, Ph.D., President and CEO Tel: (519) 858-5184 firstname.lastname@example.org www.sernova.com
Ray Matthews & Associates Tel: (604) 818-7778 email@example.com www.raymatthews.ca
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials and that Sernova will be able to raise additional capital to fund its clinical programs including its planned US clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.